Safety and immunogenicity of the epicutaneous reactivation of pertussis toxin immunity in healthy adults: a phase I, randomized, double-blind, placebo-controlled trial
Olga Chatzis(Cliniques Universitaires Saint-Luc), Claire‐Anne Siegrist(University of Geneva), Lucie Mondoulet(DBV Technologies (France)), Marie Rohr(Service de Santé de la Jeunesse), A. De Gea-Hominal(University Hospital of Geneva), Wassana Wijagkanalan, Alain Matthey, Hong Thai Pham, Pierre‐Louis Hervé(DBV Technologies (France)), Angela Huttner(University Hospital of Geneva), C. Hayem(DBV Technologies (France)), Géraldine Blanchard‐Rohner(University of Geneva), Pierre‐Henri Benhamou(DBV Technologies (France)), M Roux(DBV Technologies (France)), P H Lambert(University Hospital of Geneva), Garance Gutknecht, Benjamin Pelletier(DBV Technologies (France)), Barbara Lemaître
Cited by 14
Related Papers
Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum
|Antimicrobial Resistance and Infection Control|2013|454
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe
|New England Journal of Medicine|2015|412
How to use biomarkers of infection or sepsis at the bedside: guide to clinicians
|Intensive Care Medicine|2023|293
Influence of <i>Mycobacterium</i> <i>bovis</i> Bacillus Calmette-Guerin on Antibody and Cytokine Responses to Human Neonatal Vaccination
|The Journal of Immunology|2002|290
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial
|The Lancet Infectious Diseases|2015|278